NeoGenomics, Inc. (NASDAQ:NEO) Shares Sold by Sei Investments Co.
Sei Investments Co. decreased its stake in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 0.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 85,233 shares of the medical research company’s stock after selling 418 shares during the period. Sei Investments Co. owned approximately 0.08% of NeoGenomics worth $3,145,000 as of its most recent SEC filing.
Several other hedge funds also recently added to or reduced their stakes in NEO. Cullen Frost Bankers Inc. bought a new stake in shares of NeoGenomics in the 2nd quarter worth $31,000. Valeo Financial Advisors LLC grew its holdings in NeoGenomics by 150.0% during the third quarter. Valeo Financial Advisors LLC now owns 1,000 shares of the medical research company’s stock worth $37,000 after acquiring an additional 600 shares during the period. Fiduciary Planning LLC bought a new stake in NeoGenomics in the third quarter worth about $41,000. Flagship Harbor Advisors LLC lifted its holdings in NeoGenomics by 48.0% in the 3rd quarter. Flagship Harbor Advisors LLC now owns 1,310 shares of the medical research company’s stock valued at $48,000 after acquiring an additional 425 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale bought a new position in shares of NeoGenomics during the 3rd quarter valued at about $55,000. Institutional investors own 91.67% of the company’s stock.
NEO has been the subject of several recent research reports. Craig Hallum increased their target price on shares of NeoGenomics from $42.00 to $50.00 and gave the company a “buy” rating in a research note on Wednesday, October 28th. Guggenheim initiated coverage on NeoGenomics in a research note on Friday, August 28th. They set a “buy” rating and a $46.00 price objective for the company. ValuEngine lowered NeoGenomics from a “buy” rating to a “hold” rating in a research report on Monday, November 2nd. Morgan Stanley started coverage on NeoGenomics in a research report on Wednesday, September 9th. They issued an “overweight” rating and a $46.00 price target for the company. Finally, Zacks Investment Research cut NeoGenomics from a “strong-buy” rating to a “hold” rating in a research note on Friday, August 7th. Two equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the company’s stock. NeoGenomics presently has a consensus rating of “Buy” and a consensus target price of $40.96.
In related news, insider George Cardoza sold 52,926 shares of NeoGenomics stock in a transaction on Tuesday, November 24th. The shares were sold at an average price of $45.19, for a total value of $2,391,725.94. Following the completion of the sale, the insider now owns 423,828 shares of the company’s stock, valued at approximately $19,152,787.32. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Oort Douglas M. Van sold 340,000 shares of the company’s stock in a transaction on Monday, November 16th. The stock was sold at an average price of $42.01, for a total transaction of $14,283,400.00. Following the completion of the sale, the chief executive officer now owns 2,384,038 shares of the company’s stock, valued at $100,153,436.38. The disclosure for this sale can be found here. In the last three months, insiders have sold 850,828 shares of company stock valued at $34,056,727. Insiders own 6.50% of the company’s stock.
NASDAQ NEO opened at $47.36 on Friday. The company has a debt-to-equity ratio of 0.25, a current ratio of 6.54 and a quick ratio of 6.22. The firm has a market capitalization of $5.26 billion, a price-to-earnings ratio of -1,578.14 and a beta of 0.68. The company has a 50 day simple moving average of $41.98 and a 200-day simple moving average of $35.92. NeoGenomics, Inc. has a 52-week low of $20.47 and a 52-week high of $47.55.
NeoGenomics (NASDAQ:NEO) last issued its earnings results on Tuesday, October 27th. The medical research company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02. NeoGenomics had a negative net margin of 1.16% and a positive return on equity of 0.71%. The company had revenue of $125.40 million during the quarter, compared to analyst estimates of $126.23 million. During the same quarter last year, the business posted $0.07 EPS. The company’s revenue for the quarter was up 19.8% on a year-over-year basis.
NeoGenomics Company Profile
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States, as well as laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company’s laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.
Further Reading: The benefits and drawbacks of dollar cost averaging
Want to see what other hedge funds are holding NEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NeoGenomics, Inc. (NASDAQ:NEO).
Receive News & Ratings for NeoGenomics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for NeoGenomics and related companies with MarketBeat.com’s FREE daily email newsletter.
Original Source